ChemoCentryx, Inc.
CCXI
CCXI was delisted on the 19th of October, 2022.
183 hedge funds and large institutions have $2.82B invested in ChemoCentryx, Inc. in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 69 increasing their positions, 74 reducing their positions, and 27 closing their positions.
7% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 74
7% less funds holding
Funds holding: 196 → 183 (-13)
19% less capital invested
Capital invested by funds: $3.49B → $2.82B (-$668M)
44% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 27
58% less call options, than puts
Call options by funds: $19M | Put options by funds: $45.7M
83% less funds holding in top 10
Funds holding in top 10: 6 → 1 (-5)
Top Buyers
| 1 |
TCM
TimesSquare Capital Management
New York
|
+$61M |
| 2 |
Morgan Stanley
New York
|
+$17.7M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$16M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$15.3M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$11.1M |
Top Sellers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$73.4M |
| 2 |
D.E. Shaw & Co
New York
|
-$28.3M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$21.7M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$21.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$17.8M |
CCXI Hedge Fund Activity: Q1 2021 in Review
183 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q1 2021, worth a combined $2.82B — down 19% from $3.49B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of CCXI and 15 opened new positions — a net loss of 12 holders — while 74 trimmed existing stakes and 69 added.
The largest buyer was TimesSquare Capital Management, adding an estimated $61M. The largest seller was RA Capital Management, cutting an estimated $73.4M.
- 183 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q1 2021, down from 196 in Q4 2020.
- Funds reported $2.82B of ChemoCentryx, Inc. stock for Q1 2021, down 19% quarter-over-quarter.
- 15 funds opened new ChemoCentryx, Inc. positions in Q1 2021 and 27 closed out, a net change of -12 holders.
- The largest ChemoCentryx, Inc. buyer in Q1 2021 was TimesSquare Capital Management, an estimated $61M added.
- The largest ChemoCentryx, Inc. seller in Q1 2021 was RA Capital Management, an estimated $73.4M sold.
Based on aggregated 13F filings for Q1 2021.